These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
353 related items for PubMed ID: 29046944
1. Complement functional tests for monitoring eculizumab treatment in patients with atypical hemolytic uremic syndrome: an update. Ardissino G, Tel F, Sgarbanti M, Cresseri D, Giussani A, Griffini S, Grovetto E, Possenti I, Perrone M, Testa S, Paglialonga F, Messa P, Cugno M. Pediatr Nephrol; 2018 Mar; 33(3):457-461. PubMed ID: 29046944 [Abstract] [Full Text] [Related]
2. Eculizumab treatment in atypical hemolytic uremic syndrome: correlation between functional complement tests and drug levels. Cugno M, Capone V, Griffini S, Grovetti E, Pintarelli G, Porcaro L, Clementi E, Ardissino G. J Nephrol; 2022 May; 35(4):1205-1211. PubMed ID: 35013983 [Abstract] [Full Text] [Related]
3. Complement functional tests for monitoring eculizumab treatment in patients with atypical hemolytic uremic syndrome. Cugno M, Gualtierotti R, Possenti I, Testa S, Tel F, Griffini S, Grovetti E, Tedeschi S, Salardi S, Cresseri D, Messa P, Ardissino G. J Thromb Haemost; 2014 Sep; 12(9):1440-8. PubMed ID: 24853860 [Abstract] [Full Text] [Related]
4. Safety and effectiveness of eculizumab for pediatric patients with atypical hemolytic-uremic syndrome in Japan: interim analysis of post-marketing surveillance. Ito S, Hidaka Y, Inoue N, Kaname S, Kato H, Matsumoto M, Miyakawa Y, Mizuno M, Okada H, Shimono A, Matsuda T, Maruyama S, Fujimura Y, Nangaku M, Kagami S. Clin Exp Nephrol; 2019 Jan; 23(1):112-121. PubMed ID: 30039480 [Abstract] [Full Text] [Related]
5. Safety and effectiveness of eculizumab for adult patients with atypical hemolytic-uremic syndrome in Japan: interim analysis of post-marketing surveillance. Kato H, Miyakawa Y, Hidaka Y, Inoue N, Ito S, Kagami S, Kaname S, Matsumoto M, Mizuno M, Matsuda T, Shimono A, Maruyama S, Fujimura Y, Nangaku M, Okada H. Clin Exp Nephrol; 2019 Jan; 23(1):65-75. PubMed ID: 29959568 [Abstract] [Full Text] [Related]
6. Eculizumab is a safe and effective treatment in pediatric patients with atypical hemolytic uremic syndrome. Greenbaum LA, Fila M, Ardissino G, Al-Akash SI, Evans J, Henning P, Lieberman KV, Maringhini S, Pape L, Rees L, van de Kar NC, Vande Walle J, Ogawa M, Bedrosian CL, Licht C. Kidney Int; 2016 Mar; 89(3):701-11. PubMed ID: 26880462 [Abstract] [Full Text] [Related]
7. Atypical haemolytic uraemic syndrome treated with the complement inhibitor eculizumab: the experience of the Australian compassionate access cohort. Mallett A, Hughes P, Szer J, Tuckfield A, Van Eps C, Cambell SB, Hawley C, Burke J, Kausman J, Hewitt I, Parnham A, Ford S, Isbel N. Intern Med J; 2015 Oct; 45(10):1054-65. PubMed ID: 26247170 [Abstract] [Full Text] [Related]
8. Atypical hemolytic uremic syndrome in the setting of complement-amplifying conditions: case reports and a review of the evidence for treatment with eculizumab. Asif A, Nayer A, Haas CS. J Nephrol; 2017 Jun; 30(3):347-362. PubMed ID: 27848226 [Abstract] [Full Text] [Related]
9. Living Donor Kidney Transplantation in Atypical Hemolytic Uremic Syndrome: A Case Series. Duineveld C, Verhave JC, Berger SP, van de Kar NCAJ, Wetzels JFM. Am J Kidney Dis; 2017 Dec; 70(6):770-777. PubMed ID: 28821363 [Abstract] [Full Text] [Related]
10. Terminal Complement Inhibitor Eculizumab in Adult Patients With Atypical Hemolytic Uremic Syndrome: A Single-Arm, Open-Label Trial. Fakhouri F, Hourmant M, Campistol JM, Cataland SR, Espinosa M, Gaber AO, Menne J, Minetti EE, Provôt F, Rondeau E, Ruggenenti P, Weekers LE, Ogawa M, Bedrosian CL, Legendre CM. Am J Kidney Dis; 2016 Jul; 68(1):84-93. PubMed ID: 27012908 [Abstract] [Full Text] [Related]
12. Efficacy and safety of eculizumab in childhood atypical hemolytic uremic syndrome in Japan. Ito N, Hataya H, Saida K, Amano Y, Hidaka Y, Motoyoshi Y, Ohta T, Yoshida Y, Terano C, Iwasa T, Kubota W, Takada H, Hara T, Fujimura Y, Ito S. Clin Exp Nephrol; 2016 Apr; 20(2):265-72. PubMed ID: 26156042 [Abstract] [Full Text] [Related]
13. Discontinuation of eculizumab maintenance treatment for atypical hemolytic uremic syndrome: a report of 10 cases. Ardissino G, Testa S, Possenti I, Tel F, Paglialonga F, Salardi S, Tedeschi S, Belingheri M, Cugno M. Am J Kidney Dis; 2014 Oct; 64(4):633-7. PubMed ID: 24656451 [Abstract] [Full Text] [Related]
14. Eculizumab in secondary atypical haemolytic uraemic syndrome. Cavero T, Rabasco C, López A, Román E, Ávila A, Sevillano Á, Huerta A, Rojas-Rivera J, Fuentes C, Blasco M, Jarque A, García A, Mendizabal S, Gavela E, Macía M, Quintana LF, María Romera A, Borrego J, Arjona E, Espinosa M, Portolés J, Gracia-Iguacel C, González-Parra E, Aljama P, Morales E, Cao M, Rodríguez de Córdoba S, Praga M. Nephrol Dial Transplant; 2017 Mar 01; 32(3):466-474. PubMed ID: 28339660 [Abstract] [Full Text] [Related]
15. Ten-year outcome of Eculizumab in kidney transplant recipients with atypical hemolytic uremic syndrome- a single center experience. Kant S, Bhalla A, Alasfar S, Alachkar N. BMC Nephrol; 2020 May 20; 21(1):189. PubMed ID: 32434487 [Abstract] [Full Text] [Related]
16. Efficacy and safety of the long-acting C5 inhibitor ravulizumab in patients with atypical hemolytic uremic syndrome triggered by pregnancy: a subgroup analysis. Gäckler A, Schönermarck U, Dobronravov V, La Manna G, Denker A, Liu P, Vinogradova M, Yoon SS, Praga M. BMC Nephrol; 2021 Jan 06; 22(1):5. PubMed ID: 33407224 [Abstract] [Full Text] [Related]